Profile picture

Doctor Zhehao Dai

The University of Tokyo, Tokyo (Japan)
Membership: ESC Professional Member
Follow
Biography
Dr. Zhehao Dai is a young cardiologist at The University of Tokyo Hospital, Tokyo, Japan. He has great interest in chronic and acute heart failure, acute and intensive cardiac care, cardiovascular imaging, and pulmonary circulation. He has been dedicated in clinical research projects regarding the above-mentioned fields in the past decade in multiple institutes.
Logo ESC

Contributor content

Serum exosomal microRNAs in patients with heart failure are correlated with myocardial DNA damage and future reverse remodeling
Presentation
Serum exosomal microRNAs in patients with heart failure are correlated with myocardial DNA damage and future reverse remodeling
Myocardial DNA damage is responsible for the relationship between genotype and treatment response in patients with dilated cardiomyopathy
Presentation
Myocardial DNA damage is responsible for the relationship between genotype and treatment response in patients with dilated cardiomyopathy
Myocardial DNA damage combined with genotype predicts heart failure outcome in various underlying diseases
Presentation
Myocardial DNA damage combined with genotype predicts heart failure outcome in various underlying diseases
Percutaneous transluminal septal myocardial ablation markedly reduces energy loss in hypertrophic obstructive cardiomyopathy: a four-dimensional flow magnetic resonance imaging study
Presentation
Percutaneous transluminal septal myocardial ablation markedly reduces energy loss in hypertrophic obstructive cardiomyopathy: a four-dimensional flow magnetic resonance imaging study
An exploratory analysis for the optimal monitoring interval of  N-terminal pro-B-type natriuretic peptide in patients with stable heart failure
Presentation
An exploratory analysis for the optimal monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure
Early initiation of oral beta-blocker improves long-term survival in patients with acute myocardial infarction who underwent primary percutaneous coronary intervention.
Presentation
Early initiation of oral beta-blocker improves long-term survival in patients with acute myocardial infarction who underwent primary percutaneous coronary intervention.

ESC 365 is supported by